Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (51-60 of 275) with videos related to

Pageof 28
Sort By:
Future Oncology (London, England)|July 24, 2014
HER2 in solid tumors: more than 10 years under the microscope; where are we now?Vittoria Martin, Federico Cappuzzo, Luca Mazzucchelli, et al.
Current Opinion in Oncology|February 7, 2013
Targeting c-MET in the battle against advanced nonsmall-cell lung cancerLorenza Landi, Gabriele Minuti, Armida D'Incecco, et al.
Oral Oncology|January 2, 2021
Role of Pembrolizumab in recurrent or metastatic head and neck carcinomaRaul Pellini, Flaminia Campo, Domenico Sergi, et al.
Oncology (Williston Park, N.Y.)|September 2, 2004
Induction therapy for early-stage non-small-cell lung cancerFederico Cappuzzo, Stefania Bartolini, Cesare Calandri, et al.
Therapeutic Advances in Medical Oncology|May 31, 2016
Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerOurania Romanidou, Lorenza Landi, Federico Cappuzzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
Crizotinib in <i>ROS1</i> and <i>MET</i> Deregulated NSCLC-ResponseLorenza Landi, Rossella Bruno, Gabriella Fontanini, et al.
Human Pathology|February 19, 2010
Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non-small cell lung cancer: a promising feature?William Sterlacci, Federico Cappuzzo, Spasenija Savic, et al.
Expert Review of Anticancer Therapy|March 31, 2015
Onartuzumab in lung cancer: the fall of Icarus?Christian Rolfo, Nele Van Der Steen, Patrick Pauwels, et al.
Lung Cancer (Auckland, N.Z.)|February 18, 2017
MET overexpression and gene amplification in NSCLC: a clinical perspectiveLorenza Landi, Gabriele Minuti, Armida D'Incecco, et al.
Translational Lung Cancer Research|September 18, 2015
Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trialsRaymond U Osarogiagbon, Federico Cappuzzo, Tudor Ciuleanu, et al.
Pageof 28

Showing results (51-60 of 275) with videos related to

Sort By:
Pageof 28
Future Oncology (London, England)|July 24, 2014
HER2 in solid tumors: more than 10 years under the microscope; where are we now?Vittoria Martin, Federico Cappuzzo, Luca Mazzucchelli, et al.
Current Opinion in Oncology|February 7, 2013
Targeting c-MET in the battle against advanced nonsmall-cell lung cancerLorenza Landi, Gabriele Minuti, Armida D'Incecco, et al.
Oral Oncology|January 2, 2021
Role of Pembrolizumab in recurrent or metastatic head and neck carcinomaRaul Pellini, Flaminia Campo, Domenico Sergi, et al.
Oncology (Williston Park, N.Y.)|September 2, 2004
Induction therapy for early-stage non-small-cell lung cancerFederico Cappuzzo, Stefania Bartolini, Cesare Calandri, et al.
Therapeutic Advances in Medical Oncology|May 31, 2016
Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerOurania Romanidou, Lorenza Landi, Federico Cappuzzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
Crizotinib in <i>ROS1</i> and <i>MET</i> Deregulated NSCLC-ResponseLorenza Landi, Rossella Bruno, Gabriella Fontanini, et al.
Human Pathology|February 19, 2010
Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non-small cell lung cancer: a promising feature?William Sterlacci, Federico Cappuzzo, Spasenija Savic, et al.
Expert Review of Anticancer Therapy|March 31, 2015
Onartuzumab in lung cancer: the fall of Icarus?Christian Rolfo, Nele Van Der Steen, Patrick Pauwels, et al.
Lung Cancer (Auckland, N.Z.)|February 18, 2017
MET overexpression and gene amplification in NSCLC: a clinical perspectiveLorenza Landi, Gabriele Minuti, Armida D'Incecco, et al.
Translational Lung Cancer Research|September 18, 2015
Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trialsRaymond U Osarogiagbon, Federico Cappuzzo, Tudor Ciuleanu, et al.
Pageof 28